PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
NTLA vs. AAPL
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between NTLA and AAPL is 0.34, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

NTLA vs. AAPL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Intellia Therapeutics, Inc. (NTLA) and Apple Inc (AAPL). The values are adjusted to include any dividend payments, if applicable.

0.00%200.00%400.00%600.00%800.00%1,000.00%1,200.00%AugustSeptemberOctoberNovemberDecember2025
-57.01%
982.64%
NTLA
AAPL

Key characteristics

Sharpe Ratio

NTLA:

-1.00

AAPL:

1.15

Sortino Ratio

NTLA:

-1.62

AAPL:

1.72

Omega Ratio

NTLA:

0.81

AAPL:

1.22

Calmar Ratio

NTLA:

-0.67

AAPL:

1.60

Martin Ratio

NTLA:

-1.71

AAPL:

4.06

Ulcer Index

NTLA:

36.81%

AAPL:

6.53%

Daily Std Dev

NTLA:

63.23%

AAPL:

22.99%

Max Drawdown

NTLA:

-94.67%

AAPL:

-81.80%

Current Drawdown

NTLA:

-94.63%

AAPL:

-11.21%

Fundamentals

Market Cap

NTLA:

$967.57M

AAPL:

$3.46T

EPS

NTLA:

-$5.50

AAPL:

$6.07

PEG Ratio

NTLA:

-0.10

AAPL:

2.08

Total Revenue (TTM)

NTLA:

$45.00M

AAPL:

$271.46B

Gross Profit (TTM)

NTLA:

$39.89M

AAPL:

$125.83B

EBITDA (TTM)

NTLA:

-$390.10M

AAPL:

$91.44B

Returns By Period

In the year-to-date period, NTLA achieves a -18.52% return, which is significantly lower than AAPL's -8.16% return.


NTLA

YTD

-18.52%

1M

-20.97%

6M

-62.12%

1Y

-62.36%

5Y*

-8.29%

10Y*

N/A

AAPL

YTD

-8.16%

1M

-7.93%

6M

2.76%

1Y

20.64%

5Y*

24.45%

10Y*

25.22%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

NTLA vs. AAPL — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NTLA
The Risk-Adjusted Performance Rank of NTLA is 55
Overall Rank
The Sharpe Ratio Rank of NTLA is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of NTLA is 44
Sortino Ratio Rank
The Omega Ratio Rank of NTLA is 66
Omega Ratio Rank
The Calmar Ratio Rank of NTLA is 99
Calmar Ratio Rank
The Martin Ratio Rank of NTLA is 22
Martin Ratio Rank

AAPL
The Risk-Adjusted Performance Rank of AAPL is 7979
Overall Rank
The Sharpe Ratio Rank of AAPL is 8181
Sharpe Ratio Rank
The Sortino Ratio Rank of AAPL is 7575
Sortino Ratio Rank
The Omega Ratio Rank of AAPL is 7373
Omega Ratio Rank
The Calmar Ratio Rank of AAPL is 8787
Calmar Ratio Rank
The Martin Ratio Rank of AAPL is 7777
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NTLA vs. AAPL - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Apple Inc (AAPL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for NTLA, currently valued at -1.00, compared to the broader market-2.000.002.004.00-1.001.15
The chart of Sortino ratio for NTLA, currently valued at -1.62, compared to the broader market-4.00-2.000.002.004.00-1.621.72
The chart of Omega ratio for NTLA, currently valued at 0.81, compared to the broader market0.501.001.502.000.811.22
The chart of Calmar ratio for NTLA, currently valued at -0.67, compared to the broader market0.002.004.006.00-0.671.60
The chart of Martin ratio for NTLA, currently valued at -1.71, compared to the broader market-10.000.0010.0020.0030.00-1.714.06
NTLA
AAPL

The current NTLA Sharpe Ratio is -1.00, which is lower than the AAPL Sharpe Ratio of 1.15. The chart below compares the historical Sharpe Ratios of NTLA and AAPL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.50-1.00-0.500.000.501.001.502.00AugustSeptemberOctoberNovemberDecember2025
-1.00
1.15
NTLA
AAPL

Dividends

NTLA vs. AAPL - Dividend Comparison

NTLA has not paid dividends to shareholders, while AAPL's dividend yield for the trailing twelve months is around 0.43%.


TTM20242023202220212020201920182017201620152014
NTLA
Intellia Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
AAPL
Apple Inc
0.43%0.40%0.49%0.70%0.49%0.61%1.04%1.79%1.45%1.93%1.93%1.67%

Drawdowns

NTLA vs. AAPL - Drawdown Comparison

The maximum NTLA drawdown since its inception was -94.67%, which is greater than AAPL's maximum drawdown of -81.80%. Use the drawdown chart below to compare losses from any high point for NTLA and AAPL. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-94.63%
-11.21%
NTLA
AAPL

Volatility

NTLA vs. AAPL - Volatility Comparison

Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 21.01% compared to Apple Inc (AAPL) at 7.18%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than AAPL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%30.00%AugustSeptemberOctoberNovemberDecember2025
21.01%
7.18%
NTLA
AAPL

Financials

NTLA vs. AAPL - Financials Comparison

This section allows you to compare key financial metrics between Intellia Therapeutics, Inc. and Apple Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab